Approval · Notice of Compliance 29042 · 2022
DOVATO: Notice of Compliance 29042
Issued September 21, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29042
- Date
- September 21, 2022
- Company
- Viiv Healthcare UlcMontreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Safety updates to the Product Monograph (PM) regarding pregnancy and breast-feeding, and PM conversion to the 2020 format.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| DOVATO | Not yet assigned | — |
Medicinal ingredients
- LAMIVUDINE 300 MG per TAB
- DOLUTEGRAVIR SODIUM 50 MG per TAB